GlassScriptPhysician profile
Andrew Erian
NPI 1902167323
$12,150.44
in general payments reported to CMS, 2019-2025
57 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $1,293 · 2021: $1,679 · 2022: $2,145 · 2023: $2,254 · 2024: $1,683 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,631.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,410.84 | 2021-2025 | |
| Ucb, INC. | $726.59 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Emd Serono, INC. | $594.76 | 2019-2023 | Mavenclad |
| Lilly USA, LLC | $591.57 | 2019-2024 | Emgality, Amyvid |
| Allergan, INC. | $550.77 | 2019-2021 | |
| Eisai INC. | $438.11 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $322.10 | 2019-2022 | |
| Amgen INC. | $313.68 | 2019-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $306.02 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $284.84 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $272.44 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $268.51 | 2019-2022 | |
| Celgene Corporation | $264.22 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $263.72 | 2023-2024 | Aptiom |
| E.R. Squibb & Sons, L.L.C. | $261.09 | 2021-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Erian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.